T

Thermo Fisher Scientific

Lab supplies, instruments, and biopharma services

Quality Engineering Manager

Full-TimePosted on 9/29/2026
$112.5k - $150k/yr+ Annual bonus
Senior
Bachelor's
Fremont, CA, USA
In Person

About the job

Requirements
  • A bachelor's degree in Engineering, Science, Quality, or a related technical discipline, or comparable experience in lieu of the degree.
  • Typically, at least 7 years of progressive experience in Quality Engineering, Manufacturing Engineering, Product Engineering, or a related technical function within a regulated environment.
  • Knowledge of and ability to translate and apply 21 CFR Part 820, ISO 13485, ISO 14971, IVDD, IVDR, and/or MDSAP requirements.
  • Prior people-leadership, supervisory, and/or demonstrated technical-leadership experience.
  • Demonstrated experience with nonconformance and deviation investigations, corrective and preventive actions (CAPA), root-cause analysis, and risk management.
  • Experience supporting product or process changes, design activities, manufacturing operations, and/or new product introduction.
  • Strong analytical and structured problem-solving capabilities.
  • Demonstrated ability to influence and collaborate effectively across Engineering, Operations, and other functions.
  • Strong written and verbal communication skills.
  • Ability to handle difficult situations expertly and thoughtfully.
  • Ability to communicate effectively orally and in writing and work with employees at all organizational levels.
  • Demonstrated problem-solving and troubleshooting skills.
  • Ability to work proactively and independently without close supervision while producing quality work.
  • Proficiency with Microsoft Office applications (Outlook, PowerPoint, Word, Excel, and Visio), Microsoft Teams, Smartsheet, and Adobe Acrobat.
  • Experience managing people and talent development.
  • Strong decision-making skills and understanding of when escalation is required.
Responsibilities
  • Lead, coach, and develop the Quality Engineering team by establishing clear responsibilities, priorities, and performance expectations.
  • Manage day-to-day allocation of Quality Engineering resources according to product, project, compliance, and business risk.
  • Build team technical capability through coaching, development planning, cross-training, and standardized Quality Engineering practices.
  • Establish and monitor Quality Engineering performance metrics and use data to identify risks, trends, and improvement opportunities.
  • Provide technical guidance and escalation support for complex or high-risk quality issues.
  • Promote accountability, collaboration, continuous improvement, and quality ownership.
  • Establish procedures that simplify processes and workflows while maintaining compliance and documentation standards for 21 CFR Part 820, ISO 13485, ISO 14971, IVDD, IVDR, and/or MDSAP.
  • Ensure CAPAs, nonconformances, deviations, and complaints are implemented according to company procedures and advise teams on completing those processes effectively.
  • Lead regular interdepartmental and cross-functional review board meetings to ensure issues are reviewed and addressed promptly in accordance with company goals and regulatory requirements.
  • Provide Quality Engineering leadership for product and process design and development, transfer, design controls, and new product introduction activities.
  • Partner with Engineering and other functions to incorporate quality requirements and risk controls early in product and process development.
  • Support design and process reviews, qualification and validation activities, change implementation, and manufacturing readiness.
  • Ensure Quality deliverables for new product introduction projects are defined, resourced, and completed according to project requirements.
  • Identify potential product and process risks before implementation and drive appropriate mitigation strategies.
  • Lead and facilitate risk-management activities for products, processes, and changes.
  • Ensure risk assessments are technically sound, documented, and translated into effective controls.
  • Promote consistent risk-based decision-making across functions.
  • Ensure emerging risks identified through complaints, deviations, nonconformances, CAPAs, and operational data are evaluated and incorporated into ongoing risk management.
  • Support post-market surveillance and vigilance activities.
  • Provide Quality Engineering oversight for nonconformances and deviations, ensuring timely and technically robust investigations.
  • Ensure appropriate containment, product-impact assessment, root-cause analysis, and disposition of affected material or product.
  • Partner with other functions to reduce recurring events and improve right-first-time performance.
  • Monitor nonconformance and deviation trends and proactively initiate systemic improvement activities.
  • Provide leadership and technical oversight for corrective and preventive actions.
  • Ensure investigations identify true root causes where possible and CAPA plans address systemic issues.
  • Ensure actions are risk-based, completed promptly, and supported by appropriate effectiveness verification.
  • Analyze CAPA trends and identify opportunities to prevent recurrence across products, processes, or operations.
  • Provide Quality Engineering support for complaint investigations, particularly where manufacturing, product, or process expertise is needed.
  • Connect complaint findings to risk management, CAPA, nonconformance, and continuous-improvement processes.
  • Identify and escalate significant or recurring product-quality trends.
  • Lead or support Quality Engineering initiatives to improve product quality, process capability, reliability, and operational performance.
  • Use quality data, statistical methods, and trend analyses to identify proactive improvement opportunities.
  • Partner with Operations and Engineering to reduce defects, deviations, scrap, rework, and other sources of poor quality.
  • Standardize and simplify Quality Engineering processes and tools.
  • Champion Lean, problem-solving, and continuous-improvement methodologies within the Quality Engineering organization.
  • Ensure Quality Engineering activities comply with applicable regulations, standards, procedures, and company Quality System requirements.
  • Support internal, customer, and regulatory audits and inspections as the Quality Engineering subject-matter leader.
  • Ensure audit observations associated with Quality Engineering are investigated and addressed effectively.
  • Maintain inspection readiness within the function.
  • Promptly escalate significant product-quality, compliance, or business risks to the Senior Manager, Quality.
  • Support Management Review and other Quality governance processes by providing relevant Quality Engineering metrics, trends, risks, and improvement plans.
  • Serve as the primary Quality Engineering partner to Operations, Engineering, and applicable product-development functions.
  • Influence cross-functional decisions to consider product quality, customer impact, compliance, and business risk.
  • Build effective working relationships across functions and resolve competing priorities through risk-based decision-making.
  • Represent Quality Engineering on project teams, operational reviews, and other cross-functional forums.
  • Translate Quality requirements into practical business-enabling solutions that maintain appropriate compliance and product-quality controls.
  • Recruit, onboard, coach, and retain a capable Quality Engineering organization.
  • Establish individual objectives aligned with Quality and business priorities.
  • Conduct performance and development discussions and provide timely feedback.
  • Develop technical depth and succession capability within the Quality Engineering team.
  • Set the expectation that Quality Engineers act as proactive business partners and technical problem solvers rather than primarily as reviewers or approvers.
Desired Qualifications
  • Working knowledge of statistical Quality Engineering techniques and process capability, and knowledge of Power BI.
  • Lean or Six Sigma experience or certification.
  • ASQ CQE, CMQ/OE, or a related certification.
  • Experience leading Quality Engineers in a complex manufacturing environment.

About the company

T

Thermo Fisher Scientific

View

Thermo Fisher Scientific supplies labs, hospitals, and biotech firms with a broad range of products and services, from basic lab consumables to advanced analytical instruments and outsourced drug development. Its offerings work by combining high-tech instruments for genomics, diagnostics, and research with consumables and a global distribution network to deliver end-to-end workflows that turn samples into data and insights. The company differentiates itself through its massive, diversified portfolio and its integrated end-to-end reach—from tools and reagents to support services—built on the legacy of Fisher Scientific’s distribution strength and Thermo Electron’s instrument innovation, backed by a history of strategic acquisitions. The goal is to be the dominant partner in science and healthcare by enabling researchers and clinicians to perform work more efficiently and at larger scale, spanning discovery, development, and manufacturing.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $11.99 billion, with 13% adjusted EPS growth.
  • May 2026 Precure with Mayo Clinic targets a million-biospecimen dataset and proteomics leadership.
  • June 2026 NVIDIA, September 2026 Evosep, and CHO-K1 launches widen Thermo Fisher’s platform pull.

What critics are saying

  • Organic revenue grew only 1% in Q1 2026, exposing acquisition dependence.
  • The August 2026 microbiology sale removed $645 million revenue and cut Specialty Diagnostics depth.
  • Clario’s $8.875 billion deal needs $175 million synergies; failure damages 2027 earnings credibility.

What makes Thermo Fisher Scientific unique

  • Thermo Fisher spans consumables, instruments, services, and trial data across every lab workflow.
  • March 2026 Clario added endpoint-data infrastructure, linking instruments to clinical-trial evidence generation.
  • Thermo Fisher’s 2026 launches, from CHO-K1 media to Multiskan Ease, cover routine lab demand.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Fertility Treatment Support

Family Planning Benefits

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Company News

Yahoo Finance
Sep 28th, 2026
Thermo Fisher Scientific to resell Evosep Eno separation platform for proteomics workflows

Evosep has entered a reseller agreement with Thermo Fisher Scientific for its Evosep Eno separation platform. Through the partnership, Thermo Fisher Scientific will offer the platform as part of its mass spectrometry solutions portfolio, combining its global reach with Evosep's separation technology. The Evosep Eno platform addresses the need for standardised proteomics in research, drug discovery, and clinical applications. It delivers robustness, ease of use, and throughput whilst minimising operational complexity. Customers will be able to purchase Evosep Eno directly through Thermo Fisher Scientific. The platform enables standardised separations across laboratories, instruments, and operators, supporting reproducible results for large-scale studies. The agreement supports applications including population studies, biomarker discovery, drug development, and clinical proteomics initiatives.

Epium Ltd
Sep 25th, 2026
AI accelerator cards reshape DNA sequencing workflows.

AI accelerator cards reshape DNA sequencing workflows. The global market for AI DNA sequencer base-calling accelerator cards is expanding as genomics workflows require faster, more accurate nucleotide identification. These specialized compute modules offload signal processing and deep-learning inference from host CPUs, reducing data-transfer bottlenecks and enabling on-instrument analytics that once depended on large data-center environments. Growth is tied to rising sequencing demand, with sequencing expenditures projected to surpass US$ 30 billion annually. Long-read and single-cell applications are increasing the need for flexible AI-optimized compute, while clinical diagnostics, research and development, and personalized medicine are key application areas. On-premise integration, cloud-connected systems, and hybrid edge deployments are shaping adoption models. NVIDIA, Intel, Illumina, and Thermo Fisher Scientific lead the competitive field through GPU, ASIC, FPGA, and platform-specific approaches. Illumina has introduced the NovaBase AI card, while Thermo Fisher Scientific offers the Ion Torrent Accelerate Card. AMD, Xilinx, Hewlett Packard Enterprise, Cisco, Qualcomm, IBM, Pacific Biosciences, Oxford Nanopore Technologies, Roche Sequencing Solutions, BGI Genomics, and QIAGEN are pursuing specialized roles across the ecosystem. Europe is positioned as a highly advanced market due to strong research networks, privacy regulation, and sustainability priorities. North America benefits from federal research funding and biotech activity, while Asia-Pacific shows strong potential through expanding genomics infrastructure in China, Japan, South Korea, and India.

MarketScreener
Sep 23rd, 2026
Thermo Fisher Scientific inc. launches Gibco? CHO-K1 Catalog Panel media and feed.

Thermo Fisher Scientific inc. launches Gibco? CHO-K1 Catalog Panel media and feed. Published on 09/23/2026 at 11:43 am EDT S&P Capital IQ Thermo Fisher Scientific announced the Gibco? CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell lines. Available in liquid and dry powder media (DPM) formats, the panel can offer flexible options for process development, scale-up, and manufacturing. The panel consists of multiple basal media and feed combinations designed for a broad range of CHO-K1 cell lines, helping development teams rapidly identify medium and feed combinations that support higher performance. The chemically defined (CD), animal origin-free (AOF) formulations are cGMP-ready to support regulatory considerations. The Gibco CHO-K1 Catalog Panel helps upstream process development teams identify high-performing media and feed combinations. In a 14-day fed-batch study using a CHO-K1 GS cell line, select panel combinations demonstrated: · Up to 73% higher titer compared with the benchmark catalog media and feeds tested · Up to 202% higher peak viable cell density compared with the benchmark products tested · Strong product quality performance across tested conditions A cGMP-ready portfolio of basal and feed media for CHO-K1 cell culture and protein production. Biologics and biosimilars developers using CHO-K1 cell lines. It helps provide multiple ready-to-use media and feed options for evaluating and optimizing diverse CHO-K1 cell culture workflows. The panel combines demonstrated productivity and product quality performance with CD, AOF, cGMP-ready formulations and scalable liquid and DPM formats to support CHO-K1 process development through manufacturing. (C) S&P Capital IQ - Business Wire - 2026

Zyme Communications
Sep 22nd, 2026
Nuclera appoints Carl Raimond as Chief Executive Officer.

Nuclera appoints Carl Raimond as Chief Executive Officer. * Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific * Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer Cambridge, UK, and Boston, MA, USA, 22 September 2026: Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the appointment of Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera's co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships. The leadership transition marks the next phase in Nuclera's evolution as the Company builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. The combination of Carl's experience scaling life-science businesses with Michael's scientific leadership and deep understanding of Nuclera's technology and markets will support the Company as it expands adoption of its platform across priority life-science workflows. Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate the speed of protein science, with current focus areas including full-length IgG antibody screening, challenging membrane protein synthesis, and soluble protein expression. In May 2026, the Company launched antibody service capabilities to support early experimental triage for antibody discovery programs, complementing its eProtein Discovery(TM) system for in-house protein expression and screening. The Company is also extending its antibody strategy beyond centralized service delivery. Nuclera is advancing early partner work toward customer-site antibody screening workflows, designed to bring cell-free expression and binding triage closer to AI-enabled discovery teams and reduce the delay between computational design and experimental evidence. Carl joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. An experienced life-sciences executive, Carl has also held senior leadership roles at PerkinElmer, Agilent Technologies and Affymetrix. As Chief Scientific and Business Officer, Michael will focus on scientific strategy, market development and strategic partnerships, working closely with Carl as the Company enters its next phase of growth whilst maintaining continuity in Nuclera's scientific direction. Carl Raimond, CEO at Nuclera, said: "Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I'm excited to join the Company as we sharpen our focus on customer adoption, commercial execution, and expanding applications of our technology across life-science workflows. Michael's scientific leadership remains central to Nuclera's future, and I look forward to working with him and the team to translate this strong technology foundation into impactful solutions for our customers." Dr Michael Chen, co-founder and Chief Scientific and Business Officer at Nuclera, commented: "As a structural biologist, I know firsthand the time and frustration protein production can cost a development program. That frustration is part of why we started Nuclera. I'm incredibly proud of what the team has built and the difference our technology is already making for protein scientists. Now, we've reached an important point in the Company's evolution, and Carl is the right CEO to lead us forward. Carl's experience building and scaling life-science businesses, combined with his understanding of the opportunity ahead, will be a huge asset to Nuclera. I'm excited to work alongside him to bring that impact to every benchtop."

Cambridge Innovation Capital
Sep 22nd, 2026
Nuclera appoints ex-Thermo Fisher exec Carl Raimond as CEO.

Nuclera appoints ex-Thermo Fisher exec Carl Raimond as CEO. Business Weekly 22 Sep 2026 Cambridge biotech company Nuclera has appointed Carl Raimond as CEO in a move that sees co-founder Dr Michael Chen transition to the role of Chief Scientific and Business Officer. The company says the leadership change marks the next phase in Nuclera's evolution as it builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. Raimond joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. As Chief Scientific and Business Officer, Dr Michael Chen will focus on scientific strategy, market development and strategic partnerships. Raimond said: "Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I'm excited to join the Company as Cambridge Innovation Capital plc sharpen its focus on customer adoption, commercial execution, and expanding applications of its technology across life-science workflows. "Michael's scientific leadership remains central to Nuclera's future, and I look forward to working with him and the team to translate this strong technology foundation into impactful solutions for our customers." Nuclera is applying its cell-free protein synthesis and digital microfluidics capabilities to accelerate the speed of protein science, with current focus areas including full-length IgG antibody screening, challenging membrane protein synthesis, and soluble protein expression. In May 2026, the Company launched antibody service capabilities to support early experimental triage for antibody discovery programs, complementing its eProtein Discovery(TM) system for in-house protein expression and screening. The Company is also extending its antibody strategy beyond centralised service delivery. Nuclera is advancing early partner work toward customer-site antibody screening workflows, designed to bring cell-free expression and binding triage closer to AI-enabled discovery teams and reduce the delay between computational design and experimental evidence. Dr Chen said: "As a structural biologist, I know firsthand the time and frustration protein production can cost a development program. That frustration is part of why Cambridge Innovation Capital plc started Nuclera. I'm incredibly proud of what the team has built and the difference its technology is already making for protein scientists. "Now, we've reached an important point in the Company's evolution, and Carl is the right CEO to lead us forward. Carl's experience building and scaling life-science businesses, combined with his understanding of the opportunity ahead, will be a huge asset to Nuclera. I'm excited to work alongside him to bring that impact to every benchtop."